Melanoma Treatment Market - Forecasts from 2018 to 2023

February 2018 | 97 pages | ID: M2B5E74E842EN
Knowledge Sourcing Intelligence LLP

Abstracts

The melanoma treatment market is projected to grow at the CAGR of 12.62% during the forecast period to reach a total market size of US$5.910 billion in 2023 from US$2.896 billion in 2017. Melanoma is a type of skin cancer that develops in the melanocyte cells that are responsible for producing melanin, the pigment that imparts colour to the skin. It occurs when unrepaired damage to skin cells leads to their rapid multiplication, thus forming malignant tumours. The primary cause of Melanoma is prolonged exposure to ultraviolet light. If detected and treated at an early stage, the disease is almost always curable. In recent years, there has been a rise in the number of new cases reported, due to changing environmental landscape. The market for its treatment has thus witnessed significant growth. The United States in North America and Australia and New Zealand in Oceania are the largest markets for Melanoma treatment given the extremely high prevalence and robust medical research in these regions.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Melanoma Treatment value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are AstraZeneca, Novartis AG, Merck & Co. Inc. and Bristol-Myers Squibb among others.

Segmentation

The melanoma treatment market has been analysed through following segments:

By Type

• Cutaneous Melanoma
• Ocular Melanoma
• Mucosal Melanoma

By Therapy

• Surgery
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Radiation Therapy

By Geography

North America

• United States
• Canada
• Mexico
• Others

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• Italy
• Spain
• UK
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Israel
• Others

Asia Pacific

• India
• China
• Japan
• Australia
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. MELANOMA TREATMENT MARKET BY TYPE

5.1. Cutaneous Melanoma
5.2. Ocular Melanoma
5.3. Mucosal Melanoma

6. MELANOMA TREATMENT MARKET BY THERAPY

6.1. Surgery
6.2. Immunotherapy
6.3. Targeted Therapy
6.4. Chemotherapy
6.5. Radiation Therapy

7. MELANOMA TREATMENT MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. United States
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. Italy
  7.3.4. Spain
  7.3.5. UK
  7.3.6. Others
  7.3.7. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. UAE
  7.4.3. Israel
  7.4.4. Others
7.5. Asia Pacific
  7.5.1. India
  7.5.2. China
  7.5.3. Japan
  7.5.4. Australia

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Investment Analysis
8.3. Recent Deals
8.4. Strategies of Key Players

9. COMPANY PROFILES

9.1. Merck & Co. Inc.
  9.1.1. Company Overview
  9.1.2. Financials
  9.1.3. Products and Services
  9.1.4. Recent Developments
9.2. Amgen Inc.
  9.2.1. Company Overview
  9.2.2. Financials
  9.2.3. Products and Services
  9.2.4. Recent Developments
9.3. Iovance Biotherapeutics, Inc,
  9.3.1. Company Overview
  9.3.2. Financials
  9.3.3. Products and Services
  9.3.4. Recent Developments
9.4. Bristol-Myers Squibb
  9.4.1. Overview
  9.4.2. Financials
  9.4.3. Products and Services
  9.4.4. Recent Developments
9.5. F. Hoffmann-La Roche Ltd
  9.5.1. Company Overview
  9.5.2. Financials
  9.5.3. Products and Services
  9.5.4. Recent Developments
9.6. Eisai Co., Ltd.
  9.6.1. Company Overview
  9.6.2. Financials
  9.6.3. Products and Services
  9.6.4. Recent Developments
9.7. Novartis AG
  9.7.1. Company Overview
  9.7.2. Financials
  9.7.3. Products and Services
  9.7.4. Recent Developments
9.8. Pfizer Inc.
  9.8.1. Company Overview
  9.8.2. Financials
  9.8.3. Products and Services
  9.8.4. Recent Developments
9.9. Sanofi
  9.9.1. Company Overview
  9.9.2. Financials
  9.9.3. Products and Services
  9.9.4. Recent Developments
9.10. AstraZeneca
  9.10.1. Company Overview
  9.10.2. Financials
  9.10.3. Products and Services
  9.10.4. Recent Developments

List Of Figures

LIST OF FIGURES

List Of Tables

LIST OF TABLES